Skip survey header

JADPRO Regional Lectures: Immunotherapy: Melanoma & NSCLC Case Studies - Pre-Test

Case Studies in Melanoma and Case Studies in Non-Small Cell Lung Cancer

A continuing education activity for physicians, PAs, nurse practitioners, clinical nurse specialists, advanced degree nurses, oncology and hematology nurses, and pharmacists.

The immunotherapy educational activity is sponsored by unrestricted educational grants from AstraZeneca Pharmaceuticals LP and Merck Sharp & Dohme Corp.   

Release date: December 1, 2017                        
Expiration date: November 30, 2018
Estimated time to complete activity: 0.50 hours


R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA
Winship Cancer Institute at Emory University

Mollie Reed, MSN, RN, ACNP-BC
Tennessee Oncology

Activity Rationale and Purpose
Immunotherapy is a rapidly growing and exciting therapeutic area of oncology. This new class of oncology agents brings a more favorable adverse effect profile than traditional chemotherapeutic agents, and in some cases, efficacy continuing beyond the treatment window.

Intended Audience
The intended audience for this enduring internet activity is physicians, PAs, nurse practitioners, clinical nurse specialists, advanced degree nurses, oncology and hematology nurses, and pharmacists who specialize in the field of oncology.

Learning Objectives
After completing this educational activity, participants should be able to:
• Differentiate between early and latent adverse effects associated with immunotherapeutic agents.

Continuing Education


This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of the Annenberg Center for Health Sciences at Eisenhower, Harborside Medical Education, and the Journal of the Advanced Practitioner in Oncology. The Annenberg Center is accredited by the ACCME to provide continuing medical education for physicians.

The Annenberg Center for Health Sciences at Eisenhower designates this enduring activity for a maximum of 0.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


The Annenberg Center for Health Sciences at Eisenhower is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation. A maximum of 0.50 contact hours may be earned for successful completion of this activity.

Provider approved by the California Board of Registered Nursing, Provider No. 13664, for 0.50 contact hours.


The knowledge-based accredited educational activity is intended for pharmacists involved in the care of cancer patients. This educational activity is provided by the Annenberg Center for Health Sciences at Eisenhower.

The Annenberg Center for Health Sciences at Eisenhower is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This program is assigned ACPE Universal Program # 0797-9999-17-103-H01-P. This program is designated for up to 0.50 contact hours (0.050 CEUs) of continuing pharmacy educational credit.

Financial Disclosures
All individuals in positions to control the content of this activity (eg, planners, faculty, content reviewers) are expected to disclose all financial relationships with commercial interests that may have a direct bearing on the subject matter of this continuing education activity. Participants have the responsibility to assess the impact (if any) of the disclosed information on the educational value of the activity.

Ms. Reed has served on speakers’ bureaus and acted as a consultant for Bristol-Myers Squibb, Genentech, Merck, Novartis, Pfizer, and Taiho.
Dr. Harvey has received consulting fees/honoraria from Bristol-Myers Squibb, and his salary is partially funded by research grants from Amgen, AstraZeneca, Bristol-Myers Squibb, Five Prime Therapeutics, Merck, Janssen, Regeneron, and Tesaro paid directly to Emory University.

Lead Nurse Planner
Dorothy Caputo, MA, BSN, RN, has nothing to disclose.

Jeannine Coronna has nothing to disclose.
Brianna Hoffner MSN, ANP-BC, AOCNP® University of Colorado Cancer Center, has served on the advisory board for Eli Lilly and Company.
Claudine Kiffer has nothing to disclose.
Pamela Hallquist Viale, RN, MS, CS, ANP, has nothing to disclose.
Patti McLafferty has nothing to disclose.
Lynn Rubin has nothing to disclose.
Annie Yueh has nothing to disclose.

Content Reviews
Moshe C. Ornstein, MD, MA, Cleveland Clinic Taussig Cancer Institute, has nothing to disclose.

Annenberg Center for Health Sciences at Eisenhower
John Bayliss, VP, Business Development, spouse is an employee of Amgen, Inc.; Charles Willis, Director, Continuing Education, consults for Pfizer Inc.; all other staff at the Annenberg Center for Health Sciences at Eisenhower have no relevant commercial relationships to disclose.

This activity has been designed to provide continuing education that is focused on specific objectives. In selecting educational activities, clinicians should pay special attention to the relevance of those objectives and the application to their particular needs. The intent of the Annenberg Center for Health Sciences, Harborside Medical Education, and JADPRO for all educational opportunities is to provide learning that will improve patient care. Clinicians are encouraged to reflect on this activity and its applicability to their own patient population.

The opinions expressed in this activity are those of the faculty and reviewers and do not represent an endorsement by Harborside Medical Education of any specific therapeutics or approaches to diagnosis or patient management.

Product Disclosure
This educational activity may contain discussion of published as well as investigational uses of agents that are not approved by the U.S. Food and Drug Administration. For additional information about approved uses, including approved indications, contraindications, and warnings, please refer to the prescribing information for each product.

How to Earn Credit
To claim credit for this activity, participants must complete the pre-assessment, view the content, pass the post-assessment with a score of 70% or greater, and complete and submit an evaluation. Content is available on

Statement of Credit: Participants who successfully complete this activity (including correctly answering the one (1) question on the learning assessment and completing and submitting the evaluation form) will be able to download a statement of credit. Participants have three (3) attempts available to pass the assessment.